Introduction {#Sec1}
============

Breast cancer is the most frequent cancer in women and one of the most common causes of cancer-related death among women in the world \[[@CR1]\]. In addition to traditional prognostic factors (e.g., tumor size, lymph node status, tumor histology), new clinical or biological markers are the goal of ongoing searches to improve management of this disease.

Body composition seems to be a factor of interest in oncology and refers to the amount and distribution of lean tissue and adipose tissue in the human body. Different parameters can be evaluated to assess body composition, but the best-known parameter is body mass index (BMI), defined as weight/height^2^ (kg/m^2^) \[[@CR2]\]. It has been commonly used to assess nutritional status in cancer, but the role of this anthropometric tool in breast cancer is unclear. Some studies have shown that overweight and obesity are strong risk factors for breast cancer \[[@CR3]\], and they are described as prognostic factors for disease recurrence and shorter overall survival (OS) compared to normal-weight patients \[[@CR4]--[@CR6]\]; however, other studies have not confirmed the prognostic role of BMI in breast cancer \[[@CR7]--[@CR9]\].

BMI thus seems insufficient on its own. For example, sarcopenic obesity refers to obese cancer patients who lose muscle mass but for whom the weight loss may be masked by excess fat mass if BMI is considered on its own \[[@CR10]\]. Other parameters that are more representative of body composition have been highlighted thanks to the development of image analysis methods such as computed tomography (CT) scans \[[@CR11]\]. Among the compartments that can be distinguished on CT, skeletal muscle mass (SMM), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and muscle fat infiltration or inter-muscular adipose tissue areas (IMAT) have been analyzed \[[@CR12]\].

Body composition is an important feature because it affects the efficacy and toxicity of chemotherapy in different cancers \[[@CR13], [@CR14]\] and is associated with patient outcomes \[[@CR15], [@CR16]\]. In breast cancer \[[@CR17]\], some studies have analyzed the association between body composition and outcomes or toxicities in various situations \[[@CR18]--[@CR21]\].

The objective of this work was to investigate the impact of body composition on outcomes in patients with early breast cancer for whom a CT scan was performed because of aggressive clinico-pathological characteristics.

Material and methods {#Sec2}
====================

Patients {#Sec3}
--------

This retrospective study was performed at Limoges University Hospital on patients treated from March 2007 to June 2016. They were selected from the institution's database according to all following criteria: (1) Patients had early breast cancer for which a CT scan was performed for staging because of aggressive clinico-pathological characteristics; (2) CT scan imaging was performed in the hospital before the beginning of chemotherapy and images were saved in the institution's radiology database; (3) clinico-pathological data, including age, menopausal status, anthropometric measures, tumor characteristics, and treatment, had to be available and were extracted from the medical records and electronic database. Patients whose breast cancer was diagnosed as metastatic were excluded.

Clinical data were collected in accordance with French bioethics laws regarding patient information and consent. Patients also sign informed consent for use of data from biological samples and collections at the beginning of their medical care. The use of retrospective and prospective data from the BRTS "Regional solid tumors base" was validated by the ethics committee.

Anthropometric measures {#Sec4}
-----------------------

Weight and height were recorded according to standard methods at the first appointment. Weight was measured by a nurse using the same portable digital scale (Tanita, Tokyo, Japan). Only the first weight was considered for the study. Nurses also measured height using a stadiometer (± 0.5 cm). BMI was calculated and the median BMI was used for the study. Because of the small sample size, BMI was dichotomized as \< 25 kg/m^2^ (underweight or normal) and ≥ 25 kg/m^2^ (overweight or obese), as in other studies \[[@CR13], [@CR22]\].

CT scan imaging {#Sec5}
---------------

CT scans were performed in patients with aggressive clinico-pathological factors prior to the beginning of chemotherapy and according to French recommendations \[[@CR23]\].

With standard operating procedures \[[@CR24]\], SMM, VAT, SAT, and IMAT were assessed using the average of measurements on two adjacent axial slices at the third lumbar vertebra (L3) (Fig. [1](#Fig1){ref-type="fig"}). To evaluate SMM, the following parameters were analyzed: the masses of the psoas, quadratus lumborum, transversus abdominis, external and internal obliques, rectus abdominis, and erector spinae muscles. The fat present in the psoas was not taken into account for VAT and defining IMAT.Fig. 1Axial CT image of the third lumbar vertebral region with corresponding highlighted body composition in patients: skeletal muscle mass (SMM) in red, visceral (VAT) in blue, subcutaneous (SAT) fat tissues in yellow, and muscle fat infiltration (IMAT) in green

The measured total cross-section (cm^2^) was normalized for meters squared (m^2^), expressed in units of cm^2^/m^2^, and reported respectively as the SMM, VAT, SAT, and IMAT indexes. Images were analyzed using Slice-O-Matic software (v. 4.3 Tomovision, Montreal, Canada).

Because of the lack of consensus, we defined cut-offs as previously reported:L3 skeletal muscle index \< 41.0 cm^2^/m^2^ defined sarcopenia \[[@CR15]--[@CR17], [@CR25]\];the cut-off points for the VAT, SAT, and the IMAT indexes were based on the median \[[@CR26]\]; andVAT/SAT ratio was calculated for each patient, and we divided patients according to the 50th percentiles of the VAT/SAT ratio \[[@CR27]\].

Statistical analysis {#Sec6}
--------------------

All data were collected and analyzed using STATVIEW® software (SAS Institute, Inc., Cary, NC, USA). Quantitative results were given as median ± SD and qualitative results as percentages. The significance of the difference in the variables among the groups was calculated using the chi-square test. Medians were compared with the nonparametric Mann--Whitney *U* test for ordinal variables. Overall survival (OS) was calculated from the date of diagnosis to the date of death from any cause or the date of last follow-up. Disease-free survival (DFS) in months was calculated from the date of diagnosis until disease progression or relapse. Survival curves were obtained using the Kaplan--Meier technique. Relevant variables associated with OS and DFS were examined using univariable and, where applicable, multivariable Cox proportional hazards regression. For the multivariable models, a univariable inclusion criterion of *p* ≤ 0.2 was used. All statistical tests had a level of significance established at *p* \< 0.05.

Results {#Sec7}
=======

Clinico-pathological characteristics {#Sec8}
------------------------------------

A total of 119 patients for whom all inclusion criteria were gathered were included in this study. Clinico-pathological data are presented in Table [1](#Tab1){ref-type="table"}. The median age was 56.0 years (range 21--87 years). Patient characteristics were analyzed according to body composition parameters: sarcopenia (SMM \< 41.0 cm^2^/m^2^), VAT/SAT ratio, and IMAT. Of the 119 evaluable patients, 58 were sarcopenic (48.8%) and 61 were non-sarcopenic (51.2%) without any significant differences in clinico-pathological characteristics between the two populations.Table 1Clinico-pathological characteristics of the 119 patientsCriteriaAll patientsWithout sarcopeniaWith sarcopenia*p*With a high VAT/SAT ratioWith a low VAT/SAT ratio*p*With a high IMAT indexWith a low IMAT index*p*Number (%)11961 (51.2%)58 (48.8%)55 (46.2%)64 (53.8%)62 (52.1%)57 (47.9%)Age (years) (min-max)56.0 (21--87)54. 0 (21--87)56.0 (27--83)0.363.0 (34--83)47.0 (21--87)*\< 0.0001*62.5 (34--83)48.0 (21--87)*\< 0.0001*Menopausal status; *n* (%) Postmenopausal71 (59.5)36 (60.0)35 (60.0)0.947 (85.0)23 (36.0)*\< 0.0001*45 (72.5)25 (44.0)0.8 Premenopausal48 (40.5)25 (40.0)23 (40.0)8 (15.0)41 (64.0)17 (27.5)32 (56.0)Estrogen receptor status; *n* (%)^a^ Positive88 (74.0)46 (75.0)42 (73.0)0.839 (70.0)49 (76.0)0.346 (75.0)42 (73.5)0.8 Negative30 (26.0)15 (25.0)15 (27.0)16 (30.0)14 (24.0)15 (25.0)15 (26.5)Progesterone receptor status^a^; *n* (%) Positive64 (55.0)36 (59.0)28 (49.0)0.226 (47.0)38 (60.0)0.132 (52.5)32 (56.0)0.6 Negative54 (45.0)25 (41.0)29 (51.0)29 (53.0)25 (40.0)29 (47.5)25 (44.0)HER2; *n* (%)^b^ Positive11 (9.5)7 (11.4)4 (7.0)0.43 (5.5)8 (13.0)0.15 (8.5)6 (11.0)0.7 Negative105 (90.5)54 (88.6)51 (93.0)51 (85.5)54 (87.0)54 (91.5)51 (89.0)Clinical tumor size \< 2 cm23 (19.0)8 (13.0)15 (26.0)0.0710 (18.2)13 (20.3)0.711 (17.7)12 (21.1)0.6 ≥ 2 cm96 (81.0)53 (87.0)43 (74.0)45 (81.8)51 (79.7)51 (82.3)45 (78.9)SBR grade^c^ 13 (2.5)2 (3.5)1 (1.8)0.20 (0)3 (13.0)0.11 (1.6)2 (3.0)0.7 272 (60.5)40 (70.1)32 (58.2)38 (70.0)34 (53.0)38 (62.0)34 (64.0) 337 (14.3)15 (26.4)22 (40.0)15 (30.0)22 (34.0)18 (36.4)19 (33.0)Lymph nodes; *n* (%) Negative35 (29.4)21 (34)14 (24)0.215 (27.0)20 (31.25)0.812 (19.0)23 (40.5)*0.01* Positive (\< 3)47 (39.4)25 (41)22 (38)23 (42.0)24 (37.5)25 (40.5)22 (40.5) Positive (≥ 3)37 (31.2)15 (25)22 (38)17 (31.0)20 (31.25)25 (40.5)12 (19.0)Neoadjuvant chemotherapy; *n* (%)5534 (62)21 (38)0.323 (42.0)32 (50.0)0.326 (42.0)29 (50.0)0.1Pathological complete response^d^ yes/no17/3612/225/140.56/1611/200.56/1911/170.2Adjuvant chemotherapy alone; *n* (%)64 (54)27 (44)37 (64)0.232 (58.1)32 (50.0)0.0736 (58.0)28 (49.1)0.3Adjuvant radiotherapy; *n* (%)107 (90.0)56 (91.0)51 (87.0)0.451 (87.0)56 (92.0)0.351 (87.0)56 (92.0)0.3*p*-value statistically significant at the 0.05 level*SBR*: Scarff--Bloom--Richardson; *BMI*, body mass index; *VAT*: visceral adipose tissue; *SAT*: subcutaneous adipose tissue; *IMAT*: muscle fat infiltration^a^One missing datum^b^Three missing data points^c^Seven missing data points^d^Two missing data points

Fifty-five patients (46.2%) had a high VAT/SAT ratio, and 64 patients (53.8%) had a low VAT/SAT ratio. The difference in clinico-pathological characteristics was the age and the menopausal status: patients with a high VAT/SAT ratio were older (*p* \< 0.0001) and more often postmenopausal (*p* \< 0.0001).

Sixty-two patients (52.1%) had a high IMAT index and 57 patients (47.9%) a low IMAT index. Patients with a high IMAT index were older (*p* \< 0.0001) and had more tumors with lymph node involvement (*p* = 0.01).

Anthropometric results {#Sec9}
----------------------

Anthropometric results are shown in Table [2](#Tab2){ref-type="table"}.Table 2Anthropometric results for the 119 patients included in this studyCriteriaAll patientsWithout sarcopeniaWith sarcopenia*p*With a high VAT/SAT ratioWith a low VAT/SAT ratio*p*With a high IMAT indexWith a low IMAT index*p*Patients with BMI \< 25 kg/m2 (*n* = 49)Patients with BMI ≥ 25 kg/m2 (*n* = 70)*p*Weight (kg)68.0 ± 1.477.4 ± 16.664.6 ± 12.1*\< 0.0001*70.0 ± 1.967.0 ± 2.10.273.0 ± 2.167.0 ± 1.80.156.0 ± 0.978.0 ± 1.5*\< 0.001*BMI (kg/m^2^)26.6 ± 0.5028.7 ± 4.423.5 ± 5.7*\< 0.0001*27.2 ± 0.725.5 ± 0.60.227.0 ± 0.726.0 ± 0.60.122.2 ± 0.229.7 ± 0.5*\< 0.001*SMM index (cm^2^/m^2^)42.30 ± 0.747.0 ± 5.137.1 ± 4.0*\< 0.0001*43.1 ± 1.041.2 ± 0.90.740.6 ± 0.943.5 ± 1.00.238.4 ± 0.845.4 ± 0.9*\< 0.001*Sarcopenia *n* (%)26 (47.2)32 (50.0)0.736 (58.0)22 (38.6)*0.03*35 (71.4)22 (31.4)*\< 0.001*SAT index (cm^2^/m^2^)85.9 ± 3.399.7 ± 4.469.5 ± 4.3*\< 0.0001*85.8 ± 4.086.5 ± 5.20.687.8 ± 4.684.3 ± 4.60.160.4 ± 3.3101.0 ± 4.0*\< 0.001*VAT index (cm^2^/m^2^)41.1 ± 2.244.7 ± 3.129.8 ± 2.9*0.002*52.0 ± 3.126.6 ± 2.4*\< 0.0001*45.6 ± 3.231.6 ± 2.7*0.008*23.7 ± 1.952.0 ± 2.7*\< 0.001*VAT/SAT ratio0.46 ± 0.020.49 ± 0.020.42 ± 0.020.50.6 ± 0.010.3 ± 0.03*\< 0.0001*0.5 ± 0.040.4 ± 0.03*0.03*0.41 ± 0.020.53 ± 0.02*0.0029*IMAT index (cm^2^/m^2^)3.5 ± 0.23.3 ± 0.33.9 ± 0.3*0.04*4.0 ± 2.63.3 ± 2.2*0.002*4.7 ± 0.32. 5 ± 0.1*\< 0.0001*3.4 ± 0.33.6 ± 0.30.2All results are expressed in median ± SD*BMI*, body mass index; *SMM*: skeletal muscle mass; *VAT*: visceral adipose tissue; *SAT*: subcutaneous adipose tissue; *IMAT*: muscle fat infiltration

Patients with sarcopenia compared to patients without sarcopenia had lower BMI (*p* \< 0.0001), SMM index (*p* \< 0.0001), and especially lower SAT (*p* \< 0.0001) and VAT (*p* = 0.002) indexes. The IMAT index was higher in the sarcopenia group (*p* = 0.04); however, VAT/SAT ratio was similar in the two groups (*p* = 0.5).

The median SAT was 85.9 ± 3.3 cm^2^/m^2^, and the median VAT was 41.1 ± 2.2 cm^2^/m^2^. In the group with a low VAT/SAT ratio compared to the group with a high VAT/SAT ratio, the SAT index was similar but VAT index was higher (*p* \< 0.0001). BMI and SMM index were independent of VAT/SAT ratio, and the IMAT index was higher in the group with a high VAT/SAT ratio (*p* = 0.002).

The median IMAT index was 3.5 ± 0.2 cm2/m2. A high IMAT index was associated with a high VAT index (*p* = 0.008), a high VAT/SAT ratio (*p* = 0.03), and sarcopenia (*p* = 0.03) whereas BMI and the SAT index were similar.

Obese patient characteristics according to sarcopenia {#Sec10}
-----------------------------------------------------

Among the 119 patients studied, 70 patients were with an excess of weight (BMI ≥ 25 kg/m2). According to the predefined cut-off values, 22 patients were considered with sarcopenia. Obese/overweight patients with sarcopenia were older (*p* = 0.01) and more postmenopausal (*p* = 0.009). BMI was higher in this group (*p* = 0.02) as SAT index (*p* = 0.04).

The other parameters were comparable between sarcopenic-obese/overweight patients and patients without sarcopenia.

Considering body composition parameters, no sarcopenia and IMAT index \< 4.4 cm2/m2 were significantly associated with better PFS and OS in univariate analysis. On multivariate analysis, only sarcopenia was found to be independently associated with poor PFS (hazard ratio (HR) 0.3. Confidence interval (CI) 0.1--0.9; *p* = 0.03).

Anthropometric parameters and outcomes {#Sec11}
--------------------------------------

The results of the univariate and multivariate analyses of DFS and OS are shown in Table [3](#Tab3){ref-type="table"}. Median follow-up was 52.4 (2.0--108.4) months.Table 3Univariate and multivariate analyses of body composition parameters for DFS and OS (n = 119)Disease-free survivalOverall survivalUnivariateMultivariateUnivariateMultivariateHR (95% CI)*p*HR (95% CI)*p*HR (95% CI)*p*HR (95% CI)*p*Sarcopenia: yes vs. *no*0.4 (0.2--1.1)*0.08*0.3 (0.1--0.8)*0.02*0.3 (0.09--0.8)*0.03*0.3 (0.1--0.99)*0.05*BMI *\< 25 kg/ m* ^*2*^ vs. \> 25 kg/m^2^0.4 (0.1--1.0)*0.05*2.8 (0.1--1.1)0.090.7 (0.3--1.7)0.4SAT index (cm^2^/m^2^)\
**\<** *107.7 cm* ^*2*^ */m* ^*2*^ vs. \> 107.7 cm^2^/m^2^0.5 (0.2--1.1)*0.1*0.5 (0.1--1.3)0.10.9 (0.3--2.3)0.8VAT index (cm^2^/m^2^)\
**\<** *55.6 cm* ^*2*^ */m* ^*2*^ vs. \> 55.6 cm^2^/m^2^0.4 (0.2--1.0)*0.05*1.4 (0.5--4.1)0.50.6 (0.2--1.6)0.3IMAT index (cm^2^/m^2^)\
\< 3.5 cm^2^/m^2^ vs. **\>** *3.5 cm* ^*2*^ */m* ^*2*^4.0 (1.5--10.6)*0.005*2.8 (1.0--7.8)*0.04*4.0 (1.3--12.1)*0.01*3.6 (1.2--10.8)*0.02*VAT/SAT ratio\
\< 0.69 cm^2^/m^2^ vs. **\>** *0.69 cm* ^*2*^ */m* ^*2*^2.5 (1.0--5.9)*0.03*2.0 (0.7--5.6)0.12.2 (0.9--5.6)*0.07*1.5 (0.6--3.9)0.3*BMI*: body mass index; *VAT index*: visceral adipose tissue; *SAT index*: subcutaneous adipose tissue; *IMAT index*: muscle fat infiltration

### Disease-free survival {#Sec12}

The median DFS was 17.5 (2.0--49.4) months. There were 25 relapses (21%) with 9 local relapses and 22 metastases. In the univariate analysis, sarcopenia, BMI, VAT index, IMAT index, and VAT/SAT ratio were associated with DFS and were thus included in the multivariate model. In the multivariate analysis, only two factors were significantly associated with DFS: sarcopenia and IMAT index. No sarcopenia was significantly associated with better DFS (HR 0.3; 95% CI 0.1--0.8; *p* = 0.02) and IMAT index \> 3.5 cm^2^/m^2^ with worse DFS (HR 2.8; 95% CI 1.0--7.8; *p* = 0.04). BMI was not significantly associated with DFS, but we observed a trend towards significance (*p* = 0.09) (Fig. [2](#Fig2){ref-type="fig"}). BMI is not expressed in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Disease-free survival and overall survival of patients with breast cancer based on skeletal muscle mass index (or sarcopenia) and muscle fat infiltration (IMAT) index (*n* = 119)

### Overall survival {#Sec13}

The median OS was 52.4 (2.0--108.4) months with 22 deaths (18.4%). Among the body composition parameters, sarcopenia, IMAT index, and VAT/SAT ratio were associated with OS in the univariate analysis. In the multivariate analysis, only two parameters were significantly associated with worse OS: no sarcopenia (HR 0.3; 95% CI 0.1--0.99; *p* = 0.05) and IMAT index \> 3.5 cm^2^/m^2^ (HR 3.6; 95% CI 1.2--10.8; *p* = 0.02) (Fig. [2](#Fig2){ref-type="fig"}). BMI is not expressed in Fig. [2](#Fig2){ref-type="fig"}.

Discussion {#Sec14}
==========

Our study highlighted two parameters of the body composition, sarcopenia and the IMAT index, are significantly associated with DFS and OS in patients with breast cancer. Patients with sarcopenia and a high IMAT index (\> 3.5 cm^2^/m^2^) had a poor prognosis.

Among body composition features, sarcopenia has emerged as a common parameter in many cancers \[[@CR25]\]. To our knowledge, only one study has determined the prevalence of sarcopenia in adjuvant breast cancer \[[@CR19]\]; Villaseñor et al. found that 15.9% of sarcopenic patients (*n* = 471) had been diagnosed with stage I--IIIA breast cancer. We found a higher prevalence of sarcopenia (47.8%), probably because of the imaging method used for sarcopenia evaluation; Villaseñor et al. used dual X-ray absorptiometry scans whereas we used CT scans. Both methods were validated, but a CT scan allows for more accurate evaluation of sarcopenia \[[@CR28]\]. Moreover, measurement of body composition using CT scans is easier and more reproducible, as previously reported \[[@CR17], [@CR29]\].

In addition, we found that sarcopenia was an independent factor in poor DFS and OS, as in other studies focusing on breast \[[@CR19]\] and other cancers \[[@CR17]\]. Villaseñor et al. reported that sarcopenia (\< 5.45 kg/m^2^) was associated with an increased risk of overall mortality in adjuvant breast cancer survivors (HR 2.86; 95% CI 1.67--4.89), but breast cancer-specific mortality was not statistically increased (HR 1.95; 95% CI 0.87--4.35).

In the neoadjuvant breast cancer setting, sarcopenia has been associated with OS but not with DFS \[[@CR18]\], and Iwase et al. reported that the distant DFS (DDFS) did not differ significantly between the two groups \[[@CR21]\]. The main difficulty in the study of sarcopenia is an assortment of definitions with a variety of cut-offs. A European working group on sarcopenia recommends incorporating both muscle mass and muscle function into the definition of sarcopenia \[[@CR30]\]. Our study was retrospective, so it was not possible to evaluate muscle function (strength or performance) to define sarcopenia, which was defined only by CT scan, as is commonly accepted \[[@CR17]\].

In our study, the threshold value for sarcopenia was near that of Fabbro et al. (41.0 cm^2^/m^2^ in the current work vs. 38.5 cm^2^/m^2^) \[[@CR17]\]. There is no gold standard for defining the optimal cut-off of sarcopenia in breast cancer, so we relied on prospective data and meta-analyses in different cancers. The cut-off predominantly found was fixed at 41.0 cm^2^/m^2^ \[[@CR15]--[@CR17], [@CR25]\].

The effect of the combination of sarcopenia and obesity (sarcopenic obesity) has been examined in different cancers, suggesting that sarcopenia is an independent prognostic factor of lower survival in obese patients with cancer as we showed despite our small population \[[@CR3]--[@CR6]\]. Prado et al. reported that in patients (*n* = 250) with gastrointestinal cancer or lung cancer, obese patients with sarcopenia had an increased risk of mortality (HR 4.2; 95% CI 2.4--7.2) compared to obese non-sarcopenic patients \[[@CR15]\]. In pancreatic cancer, Tan et al. reported that sarcopenia was an independent predictor of mortality among overweight/obese patients (*n* = 111) (HR02.07; 95% CI, 1.23--3.50) \[[@CR13]\].

At least, different studies show that maintaining physical exercise has positive effects and decreases sarcopenia especially in elderly patients \[[@CR31], [@CR32]\]. The fight against sarcopenia thus requires an effective screening but also by the implementation of physical activity.

We found IMAT as an independent prognosis factor of survival in breast cancer patients. We evaluated IMAT separately from other parameters, as did van Dijk et al. \[[@CR33]\]. A recent study reported that high inter-muscular adipose tissue content was predictive of an unfavorable prognosis in hepatocellular carcinoma \[[@CR34]\], but to our knowledge, the current work is the first to report a relationship between IMAT and outcomes in breast cancer.

The other parameters we examined (BMI and VAT/SAT ratio) were not associated with outcomes. The median values of VAT and SAT were taken into account because they were previously implicated as prognostic in metastatic colorectal cancer \[[@CR26]\]. To our knowledge, only one study has evaluated the relation among VAT, SAT, and outcomes in advanced breast cancer \[[@CR21]\]. In that study conducted in 172 patients with breast cancer treated in a neoadjuvant setting, the DDFS was significantly worse for the high VAT group (VAT ≥ 100 cm^2^), but high SAT (SAT ≥ 100 cm^2^) was not associated with DDFS and OS. These thresholds were based on the guideline for screening metabolic disease created by the Japan Society for the Study of Obesity \[[@CR35]\]. In other cancers, the impact of VAT and SAT remains unclear, and the variation in cut-offs can explain the difference among all studies \[[@CR36]\]. Moreover, there are differences between the two groups considering the menopausal status. It is indicated that menopause causes changes in body composition with increased visceral fat composition as Iwase et al. showed \[[@CR1]\]. The authors reported that subcutaneous fat area and visceral fat area increased significantly and skeletal muscle area decreased significantly after menopause (all *p* \< 0.05).

The limitations of our study are its retrospective nature and the relatively small number of patients. According to recommendations, CT scans are not systematically used to assess extension in breast cancer. In order to study specifically body composition, instead of including all patients with early breast cancer, we selected patients who had an initial CT assessment and were probably more severe. Finally, our multivariate analysis included only body composition criteria.

Conclusion {#Sec15}
==========

Our results suggest that the evaluation of body composition, especially sarcopenia and IMAT index based on CT scan analysis, is worth including in breast cancer management. We propose a prospective study integrating CT imaging and functional tests to validate the prognostic role of the two parameters in early breast cancer in a larger population of patients.

Clinical data were collected in accordance with the French bioethics laws regarding patient information and consent.
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